Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features

Linda Ye, Connull Leslie, Angela Jacques, Nima Mesbah Ardakani, Benhur Amanuel, Michael Millward

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may serve as a predictive marker for anti-PD-1/PD-L1 therapies. The relationship between non-small cell lung cancer PD-L1 expression and clinicopathological characteristics remains unclear and there is no population level Australian data. We report the results of PD-L1 testing in patients with non-small cell lung cancer diagnosed at major Western Australian public hospitals served by a single state Pathology provider. We analyzed PD-L1 expression by immunohistochemistry in 241 non-small cell lung cancer specimens using the 22C3 clone on a Dako autostainer platform. Tumor cell PD-L1 expression was scored as Tumor Proportion Score and categorized using pre-specified subsets of 1%, 1-49% and = 50% for correlation with clinicopathologic features. PD-L1 Tumor Proportion Score was 1% in 65 (27%) cases, 1-49% in 100 (41%) cases and = 50% in 76 (32%) cases. PD-L1-positive rate was 92% in squamous cell carcinomas and 67% in adenocarcinomas. PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003). Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations. Tumor Proportion Score >= 50% was seen in 34% (23/68), 28% (7/25) and 25% (1/4) of RAS, EGFR mutant, and ALK translocated carcinomas, respectively. There was no significant correlation between PD-L1 expression and molecular or genetic abnormalities, or other parameters including age, gender, stage, and smoking status. In our patient cohort, PD-L1 Tumor Proportion Score was significantly higher in squamous cell carcinomas and lower in adenocarcinomas. The overall prevalence of Tumor Proportion Score >= 50% is consistent with that reported in clinical trials.

Original languageEnglish
Pages (from-to)524-531
Number of pages8
JournalModern Pathology
Volume32
Issue number4
DOIs
Publication statusPublished - Apr 2019

Cite this

@article{737b536a34894faab414018d6215bc78,
title = "Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features",
abstract = "Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may serve as a predictive marker for anti-PD-1/PD-L1 therapies. The relationship between non-small cell lung cancer PD-L1 expression and clinicopathological characteristics remains unclear and there is no population level Australian data. We report the results of PD-L1 testing in patients with non-small cell lung cancer diagnosed at major Western Australian public hospitals served by a single state Pathology provider. We analyzed PD-L1 expression by immunohistochemistry in 241 non-small cell lung cancer specimens using the 22C3 clone on a Dako autostainer platform. Tumor cell PD-L1 expression was scored as Tumor Proportion Score and categorized using pre-specified subsets of 1{\%}, 1-49{\%} and = 50{\%} for correlation with clinicopathologic features. PD-L1 Tumor Proportion Score was 1{\%} in 65 (27{\%}) cases, 1-49{\%} in 100 (41{\%}) cases and = 50{\%} in 76 (32{\%}) cases. PD-L1-positive rate was 92{\%} in squamous cell carcinomas and 67{\%} in adenocarcinomas. PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003). Of the 196 non-squamous carcinomas, 35{\%} had rat sarcoma viral oncogene homolog (RAS) mutations, 13{\%} had epidermal growth factor receptor (EGFR) mutations, 2{\%} had anaplastic lymphoma kinase (ALK) translocations and 2{\%} had ROS1 translocations. Tumor Proportion Score >= 50{\%} was seen in 34{\%} (23/68), 28{\%} (7/25) and 25{\%} (1/4) of RAS, EGFR mutant, and ALK translocated carcinomas, respectively. There was no significant correlation between PD-L1 expression and molecular or genetic abnormalities, or other parameters including age, gender, stage, and smoking status. In our patient cohort, PD-L1 Tumor Proportion Score was significantly higher in squamous cell carcinomas and lower in adenocarcinomas. The overall prevalence of Tumor Proportion Score >= 50{\%} is consistent with that reported in clinical trials.",
keywords = "INFILTRATING T-CELLS, PD-L1 EXPRESSION, POOR-PROGNOSIS, PULMONARY ADENOCARCINOMA, CLINICAL-SIGNIFICANCE, PROTEIN EXPRESSION, IMMUNE ESCAPE, EGFR, PEMBROLIZUMAB, DOCETAXEL",
author = "Linda Ye and Connull Leslie and Angela Jacques and Ardakani, {Nima Mesbah} and Benhur Amanuel and Michael Millward",
year = "2019",
month = "4",
doi = "10.1038/s41379-018-0173-9",
language = "English",
volume = "32",
pages = "524--531",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group - Macmillan Publishers",
number = "4",

}

Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. / Ye, Linda; Leslie, Connull; Jacques, Angela; Ardakani, Nima Mesbah; Amanuel, Benhur; Millward, Michael.

In: Modern Pathology, Vol. 32, No. 4, 04.2019, p. 524-531.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features

AU - Ye, Linda

AU - Leslie, Connull

AU - Jacques, Angela

AU - Ardakani, Nima Mesbah

AU - Amanuel, Benhur

AU - Millward, Michael

PY - 2019/4

Y1 - 2019/4

N2 - Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may serve as a predictive marker for anti-PD-1/PD-L1 therapies. The relationship between non-small cell lung cancer PD-L1 expression and clinicopathological characteristics remains unclear and there is no population level Australian data. We report the results of PD-L1 testing in patients with non-small cell lung cancer diagnosed at major Western Australian public hospitals served by a single state Pathology provider. We analyzed PD-L1 expression by immunohistochemistry in 241 non-small cell lung cancer specimens using the 22C3 clone on a Dako autostainer platform. Tumor cell PD-L1 expression was scored as Tumor Proportion Score and categorized using pre-specified subsets of 1%, 1-49% and = 50% for correlation with clinicopathologic features. PD-L1 Tumor Proportion Score was 1% in 65 (27%) cases, 1-49% in 100 (41%) cases and = 50% in 76 (32%) cases. PD-L1-positive rate was 92% in squamous cell carcinomas and 67% in adenocarcinomas. PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003). Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations. Tumor Proportion Score >= 50% was seen in 34% (23/68), 28% (7/25) and 25% (1/4) of RAS, EGFR mutant, and ALK translocated carcinomas, respectively. There was no significant correlation between PD-L1 expression and molecular or genetic abnormalities, or other parameters including age, gender, stage, and smoking status. In our patient cohort, PD-L1 Tumor Proportion Score was significantly higher in squamous cell carcinomas and lower in adenocarcinomas. The overall prevalence of Tumor Proportion Score >= 50% is consistent with that reported in clinical trials.

AB - Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may serve as a predictive marker for anti-PD-1/PD-L1 therapies. The relationship between non-small cell lung cancer PD-L1 expression and clinicopathological characteristics remains unclear and there is no population level Australian data. We report the results of PD-L1 testing in patients with non-small cell lung cancer diagnosed at major Western Australian public hospitals served by a single state Pathology provider. We analyzed PD-L1 expression by immunohistochemistry in 241 non-small cell lung cancer specimens using the 22C3 clone on a Dako autostainer platform. Tumor cell PD-L1 expression was scored as Tumor Proportion Score and categorized using pre-specified subsets of 1%, 1-49% and = 50% for correlation with clinicopathologic features. PD-L1 Tumor Proportion Score was 1% in 65 (27%) cases, 1-49% in 100 (41%) cases and = 50% in 76 (32%) cases. PD-L1-positive rate was 92% in squamous cell carcinomas and 67% in adenocarcinomas. PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003). Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations. Tumor Proportion Score >= 50% was seen in 34% (23/68), 28% (7/25) and 25% (1/4) of RAS, EGFR mutant, and ALK translocated carcinomas, respectively. There was no significant correlation between PD-L1 expression and molecular or genetic abnormalities, or other parameters including age, gender, stage, and smoking status. In our patient cohort, PD-L1 Tumor Proportion Score was significantly higher in squamous cell carcinomas and lower in adenocarcinomas. The overall prevalence of Tumor Proportion Score >= 50% is consistent with that reported in clinical trials.

KW - INFILTRATING T-CELLS

KW - PD-L1 EXPRESSION

KW - POOR-PROGNOSIS

KW - PULMONARY ADENOCARCINOMA

KW - CLINICAL-SIGNIFICANCE

KW - PROTEIN EXPRESSION

KW - IMMUNE ESCAPE

KW - EGFR

KW - PEMBROLIZUMAB

KW - DOCETAXEL

U2 - 10.1038/s41379-018-0173-9

DO - 10.1038/s41379-018-0173-9

M3 - Article

VL - 32

SP - 524

EP - 531

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 4

ER -